Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -59.40% is 18% above its 5-year average of -72.57%, near the high end of its 5-year range (-391.42%–-14.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 68.12% above its 12-month average of -186.32%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -59.40%.
RETURN ON EQUITY (ROE)
-59.40%
RETURN ON EQUITY (ROE) AVG TTM
-186.32%
RETURN ON EQUITY (ROE) AVG 3Y
-101.54%
RETURN ON EQUITY (ROE) AVG 5Y
-72.57%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.12%
CURRENT VS 3Y AVG
+41.51%
CURRENT VS 5Y AVG
+18.15%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 392 covered companies
CURRENT VS SECTOR MEDIAN
-64.97%
vs the sector median at left
ALX Oncology Holdings Inc.
Market Cap
$162.82M
Return on Equity (ROE)
-59.40%
TTM Avg
-186.32%
3Y Avg
-101.54%
5Y Avg
-72.57%
Market Cap
$160.82M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$153.84M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$172.99M
Return on Equity (ROE)
-44.23%
TTM Avg
-36.61%
3Y Avg
-30.86%
5Y Avg
-42.66%
Market Cap
$173.04M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$152.45M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$152.16M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$174.17M
Return on Equity (ROE)
-116.42%
TTM Avg
-18.43%
3Y Avg
-136.68%
5Y Avg
-137.61%
Market Cap
$149.51M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $162.82M | -59.40% | -186.32% | -101.54% | -72.57% |
| Inogen, Inc. (INGN)vs › | $160.82M | -14.07% | -16.23% | -27.66% | -19.01% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -183.44% | -114.28% | -67.72% | -46.03% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -44.23% | -36.61% | -30.86% | -42.66% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -215.26% | -150.35% | 8.65% | -35.35% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -21.38% | -42.33% | -37.95% | -45.57% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -155.34% | -168.75% | -117.97% | -104.46% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -116.42% | -18.43% | -136.68% | -137.61% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -93.22% | -92.28% | -73.94% | -53.80% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -7104.24% | -166.54% | -137.65% | -112.46% |
ROE
-59.4%
ROA
-50.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -59.40% |
| 2026-03-31 | -58.72% |
| 2025-12-31 | -391.42% |
| 2025-09-30 | -241.09% |
| 2025-06-30 | -180.97% |
| 2025-03-31 | -147.26% |
| 2024-12-31 | -118.69% |
| 2024-09-30 | -110.49% |
| 2024-06-30 | -107.61% |
| 2024-03-31 | -101.22% |
| 2023-12-31 | -84.76% |
| 2023-09-30 | -86.54% |
| 2023-06-30 | -61.30% |
| 2023-03-31 | -53.72% |
| 2022-12-31 | -46.87% |
| 2022-09-30 | -42.24% |
| 2022-06-30 | -34.92% |
| 2022-03-31 | -27.30% |
| 2021-12-31 | -22.99% |
| 2021-09-30 | -19.16% |
| 2021-06-30 | -14.67% |
| 2021-03-31 | -13.02% |
| 2020-12-31 | -10.64% |
| 2020-09-30 | -13.78% |
| 2020-06-30 | -30.44% |
| 2020-03-31 | -20.64% |
